PIK3CA CRISPR Knockout HCT116 Stable Cell Line-T2-3

Description

The PIK3CA Human CRISPR Knockout HCT116 Cell Line - T2-3 represents a powerful tool for cancer research, specifically focusing on the role of the PIK3CA gene in colorectal cancer. By utilizing CRISPR-Cas9 technology to knockout the PIK3CA gene in the HCT116 colorectal cancer cell line, this model offers an unprecedented opportunity to study the effects of PIK3CA deletion on cancer cell growth, survival, and response to therapies. PIK3CA, a critical component of the PI3K/AKT signaling pathway, is frequently mutated in various cancers, making its study essential for understanding tumorigenesis and developing targeted treatments. This cell line enables researchers to dissect the biological consequences of PIK3CA loss, investigate compensatory pathways that may be activated in its absence, and screen for drugs that effectively target PIK3CA-deficient tumors. This cell line is invaluable for advancing our knowledge of cancer biology and paving the way for novel therapeutic strategies.